Book a Meeting

Anti-HLA DR beta Antibody, FcγRIIB Binding Enhanced (CAT#: AES-0622-ZP625) Datasheet

Target
HLA DR beta
Description
Anti-HLA DR beta FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.
Applications
Enhancing primate/human antigen eliminating
Technology
FcγRIIB selective binding technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced HLA DR beta antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Major Histocompatibility Complex, Class II, DR Beta 1
Background
Apolizumab;267227-08-7;1D10;HU1D10;K8-355;HLA-DRB1;major histocompatibility complex, class II, DR beta 1;HLA DR1B;DW2.2/DR2.2;MHC class II antigen;lymphocyte antigen DRB1;MHC class II HLA-DRw10-beta;human leucocyte antigen DRB1;MHC class II HLA-DR beta 1
Antibody Clone
AES-0622-ZP625
Description
Anti-HLA DR beta FcγRIIB Binding Enhanced Antibody achieved by modifying the Fc of the antibody to increase the affinity of the antibody with FcγRIIb.

Related Products

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.